Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
James Samuel ShannonDirector | Xilio TherapeuticsXLO | Open-market buy | 03/26 | 03/30 | 5,000 sh | $8.79 | $43,950 | +100.0% |
Kevin M. BrennanSVP, Finance and Accounting | Xilio TherapeuticsXLO | Open-market sale10b5-1 plan | 01/02 | 01/05 | 1,826 sh | $0.64 | $1,168.64 | −22.3% |
Xilio TherapeuticsXLO | Open-market sale10b5-1 plan | 01/02 | 01/05 | 7,030 sh | $0.64 | $4,499.2 | −22.1% | |
Xilio TherapeuticsXLO | Open-market buy | 25/06/16–25/06/17 | 25/06/18 | 70,000 sh2 trades | $0.69avg. | $48,300 | No record | |
Rene RussoPresident and CEO | Xilio TherapeuticsXLO | Open-market buy | 25/06/16 | 25/06/18 | 36,289 sh | $0.68 | $24,676.52 | +14.8% |
Kevin M. BrennanSVP, Finance and Accounting | Xilio TherapeuticsXLO | Open-market sale10b5-1 plan | 25/01/02 | 25/01/03 | 1,803 sh | $0.98 | $1,766.94 | −36.1% |
Xilio TherapeuticsXLO | Open-market sale10b5-1 plan | 25/01/02 | 25/01/03 | 6,954 sh | $0.98 | $6,814.92 | −35.9% | |
Gilead Sciences10% Owner | Xilio TherapeuticsXLO | Open-market buy | 24/12/18 | 24/12/19 | 1,759,978 sh | $1.04 | $1,830,377.12 | +24.0% |
Gilead Sciences10% Owner | Xilio TherapeuticsXLO | Open-market buy | 24/04/02 | 24/04/03 | 485,250 sh | $0.76 | $368,790 | +7.1% |
Xilio TherapeuticsXLO | Open-market sale | 24/02/08 | 24/02/09 | 1,000 sh2 trades | $0.64avg. | $640 | No record | |
Xilio TherapeuticsXLO | Open-market sale | 24/02/08 | 24/02/09 | 1,000 sh2 trades | $0.64avg. | $640 | No record | |
Xilio TherapeuticsXLO | Open-market sale | 24/02/08 | 24/02/09 | 1,000 sh2 trades | $0.64avg. | $640 | No record | |
Xilio TherapeuticsXLO | Open-market sale | 24/02/08 | 24/02/09 | 1,000 sh2 trades | $0.64avg. | $640 | No record | |
Xilio TherapeuticsXLO | Open-market sale | 24/02/08 | 24/02/09 | 1,000 sh2 trades | $0.64avg. | $640 | No record | |
Xilio TherapeuticsXLO | Open-market sale | 24/02/08 | 24/02/09 | 1,000 sh2 trades | $0.64avg. | $640 | No record | |
Xilio TherapeuticsXLO | Open-market sale | 24/01/11–24/01/12 | 24/01/16 | 4,235 sh4 trades | $0.85avg. | $3,600.45 | No record | |
Xilio TherapeuticsXLO | Open-market sale | 24/01/11–24/01/12 | 24/01/16 | 4,235 sh4 trades | $0.85avg. | $3,600.45 | No record | |
Xilio TherapeuticsXLO | Open-market sale | 24/01/11–24/01/12 | 24/01/16 | 4,235 sh4 trades | $0.85avg. | $3,600.45 | No record | |
Xilio TherapeuticsXLO | Open-market sale | 24/01/11–24/01/12 | 24/01/16 | 4,235 sh4 trades | $0.85avg. | $3,600.45 | No record | |
Xilio TherapeuticsXLO | Open-market sale | 24/01/11–24/01/12 | 24/01/16 | 4,235 sh4 trades | $0.85avg. | $3,600.45 | No record |
